gptkbp:instance_of
|
gptkb:Antihero
|
gptkbp:approves
|
gptkb:European_Union
gptkb:United_States
2016-02-29
|
gptkbp:atccode
|
N03 AX22
|
gptkbp:availability
|
prescription only
|
gptkbp:brand
|
gptkb:Briviact
|
gptkbp:casnumber
|
357336-20-0
|
gptkbp:chemical_formula
|
C12 H14 N2 O2
|
gptkbp:class
|
anticonvulsants
|
gptkbp:clinical_trial
|
Phase III
|
gptkbp:clinical_use
|
seizure control
|
gptkbp:composed_by
|
from 2-oxo-1-pyrrolidine acetic acid
|
gptkbp:contraindication
|
hypersensitivity
|
gptkbp:developed_by
|
gptkb:UCB_Pharma
|
gptkbp:drug_interactions
|
CYP2 C19 inhibitors
CYP3 A4 inducers
|
gptkbp:duration
|
long-term
|
gptkbp:excretion
|
urine
|
gptkbp:formulation
|
gptkb:Software_Solutions
tablets
|
https://www.w3.org/2000/01/rdf-schema#label
|
brivaracetam
|
gptkbp:indication
|
partial-onset seizures
|
gptkbp:is_monitored_by
|
side effects
seizure frequency
|
gptkbp:knockouts
|
high
|
gptkbp:lifespan
|
8 to 9 hours
|
gptkbp:market_position
|
available
|
gptkbp:mechanism_of_action
|
SV2 A ligand
|
gptkbp:metabolism
|
liver
|
gptkbp:patient_education
|
recognizing side effects
importance of adherence
drug interactions awareness
|
gptkbp:patient_population
|
adults and children
|
gptkbp:pharmacokinetics
|
linear
modulates neurotransmitter release
|
gptkbp:price
|
varies by region
|
gptkbp:provides_guidance_on
|
dose adjustment for renal impairment
follow-up required
recommended for refractory epilepsy
|
gptkbp:regulatory_compliance
|
FDA approved
EMA approved
|
gptkbp:research_focus
|
new formulations
pediatric use
long-term safety
drug combinations
|
gptkbp:route_of_administration
|
oral
|
gptkbp:side_effect
|
gptkb:depression
anxiety
dizziness
fatigue
nausea
irritability
ataxia
insomnia
weight gain
somnolence
|
gptkbp:structure
|
pyrrolidine derivative
|
gptkbp:treatment
|
adjunctive therapy
|
gptkbp:type_of_care
|
important for efficacy
|
gptkbp:used_for
|
gptkb:epilepsy
|
gptkbp:bfsParent
|
gptkb:Briviact
gptkb:Phenytoin
|
gptkbp:bfsLayer
|
7
|